BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30740643)

  • 1. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials.
    Wang X; Luo S; Gan X; He C; Huang R
    Kardiol Pol; 2019; 77(2):207-216. PubMed ID: 30740643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
    Cicero AFG; Fogacci F; Hernandez AV; Banach M;
    PLoS Med; 2020 Jul; 17(7):e1003121. PubMed ID: 32673317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
    Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
    Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Di Minno A; Lupoli R; Calcaterra I; Poggio P; Forte F; Spadarella G; Ambrosino P; Iannuzzo G; Di Minno MND
    J Am Heart Assoc; 2020 Aug; 9(15):e016262. PubMed ID: 32689862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
    Bhagavathula AS; Al Matrooshi NO; Clark CCT; Rahmani J
    Clin Drug Investig; 2021 Jan; 41(1):19-28. PubMed ID: 33368025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D; Du N; Sulaica EM; Wanat MA
    Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
    Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
    BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
    Cicero AFG; Fogacci F; Cincione I
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
    Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
    Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETC-1002: a future option for lipid disorders?
    Nikolic D; Mikhailidis DP; Davidson MH; Rizzo M; Banach M
    Atherosclerosis; 2014 Dec; 237(2):705-10. PubMed ID: 25463109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis.
    Masson W; Lobo M; Lavalle-Cobo A; Molinero G
    Clin Investig Arterioscler; 2021; 33(3):117-126. PubMed ID: 33328138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.